0.6%. [3] [4] [5] Hence, the knowledge of placebo effects is important to evaluate the efficacy of a new drug to determine its real effective in glucose control or body weight control. It is also useful for blind trials to evaluate the effect difference between treatment groups and placebo groups. Moreover, in randomized controlled trails (RCTs) or observational studies, it is useful for testing the placebo-corrected efficacy in glucose control even if the control group was an active antidiabetic drug. [1, 6, 7] With the increasing prevalence of T2DM in Asian population and the unmet need for improving glucose control, [8] [9] [10] the placebo-controlled RCTs of novel agents have been carried out in both Asian and Caucasian patients with T2DM. It was suggested that the placebo response in clinical trials represents more than just regression to the mean and passage of time; [11] well-learned and definitely understood placebo effect are likely to be related to better design and execution of diabetes trials in Asian and Caucasian populations. [12, 13] Due to the lower body mass index (BMI) and other different demographics of Asian patients compared with that of Caucasian patients [9, 14] and the complicate genetic and pharmacogenetic ethnic background [15, 16] or variable response to antidiabetic treatment, [17] [18] [19] the placebo effect of glucose control and body weight control between the two ethnicities might be different. The exact placebo effect in T2DM treatment has not been evaluated comprehensively so far, especially in Asian and Caucasian patients. If the trial was done mainly in Caucasian population (>50%), it would be classified as Caucasian group, if the trial was done mainly in Asian population (>50%), it would be classified as Asian group. [17] [18] [19] Therefore, the aim of this study was to evaluate the placebo effects of antidiabetic therapies in Asian and Caucasian T2DM patients and make comparison between the two ethnicities.
methods

Search strategy
A search using the MEDLINE database, EMBASE, and Cochrane Database was performed, from when recording began to December 2016. The strategy was performed using the following terms in English: sulfonylurea (SU); alpha glucosidase inhibitors (AGIs); metformin (MET); thiazolidinediones (TZD); dipeptidyl peptidase-4 inhibitors (DPP-4i); sodium-glucose cotransporter 2 inhibitors (SGLT2i); glucagon-like peptide-1 receptor analogues (GLP-1RA); type 2 diabetes (T2DM); placebo controlled; and randomized controlled trials. The search was conducted from June 2014 to October 2016. This meta-analysis was registered as CRD42014009373.
Study selection
To evaluate the placebo effects of antidiabetic therapies in T2DM patients, the inclusion criteria were therefore listed as follows: (1) placebo-controlled, randomized trials; (2) included T2DM participants; (3) the study duration ≥12 weeks; (4) the levels of HbA1c changed from baseline were measured in the placebo group; and (5) the ethnicity was reported in the trial.
According to the inclusion criteria, two authors (Nie L, Xu ML) independently screened the studies one by one. If there is any disagreement, a third author (Wang XR) will be consulted. Using the Cochrane instrument, we evaluated the adequacy of randomization, allocation concealment procedures, and blinding. [20] 
Data extraction
The following data were independently extracted using a standardized form. Study titles and authors, study design, the number of individuals in placebo group, patients' age, gender, BMI, diabetes duration, baseline HbA1c, duration of follow-up, and the changes of HbA1c and body weight in placebo group were all documented. If there is any disagreement, it would be resolved by discussion with another author (Yang WJ).
Definition of Asian and Caucasian
All the data would be divided according to the ethnicity of the population included. If the trial involved more than 50% Caucasian population of all patients, it would be classified as in Caucasian group; if the trial was done mainly in Asian population (>50%), it would be classified as in Asian group. [17] [18] [19] 
Statistical analysis
To compare the baseline variables between Asian and Caucasian population, data were expressed as mean ± standard deviation and were compared using t-test. A two-sided P < 0.05 was considered statistically significant. The primary end point of this meta-analysis was absolute HbA1c change relative to baseline in placebo treatment group in Asian and Caucasian T2DM patients. The mean difference (MD) in the placebo group was calculated as the change from baseline and 95% confidence interval (CI ) was also shown. The measures of effect for all continuous variables were the differences from baseline to end point. When the standard deviations (SDs) for these differences were missing, we calculated the SD of the difference with the following formula: [21] SD paired difference 2 = SD pretreatment value 2 + SD posttreatment value 2 − 2 × r × SD pretreatment value × SD posttreatment value . We used a conservative correlation coefficient (r) of 0.4.
Treatment effects were estimated by random-effect or fixed-effect pairwise meta-analysis. Higgins I 2 statistics were used to quantify the percentage of the total variance in the summary estimate due to between-study heterogeneity. Publication bias was assessed via a funnel plot vision. Meta-regression analysis was also made for the association analysis between placebo effect in HbA1c changes and baseline characteristics. Statistical testing was two-sided, with P < 0.05 considered statistically significant. All statistical analyses were performed with the STATA statistical software package (Version 11.0, StataCorp, College Station, TX, USA). We conducted this study according to the PRISMA guidelines. [22] MET treatment group, there was one study conducted in Asians and 16 studies conducted in Caucasians. There were eight studies in Asians and 35 studies in Caucasians with AGI treatment and 12 studies in Asians and 72 studies in Caucasians with TZD treatment. In DPP-4i treatment, there were 23 studies in Asians and 46 studies in Caucasians. In SGLT2i treatment, there were 11 studies in Asians and 38 studies in Caucasians. Figure 1 indicates the study selection process. This study included 63 studies with a total of 7096 Asian patients involved and 262 studies with a total of 27,477 Caucasian patients recruited. In SU treatment group, there were 22 studies conducted in Caucasian population, but no study was found to recruit Asians. In 
results
Outlines of the studies included
Methodological quality
All studies were double-blindly designed with placebo controlled. The heterogeneity was assessed for each hypoglycemic treatment. When the I 2 > 50%, the random-effect model was used, and when the I 2 ≤ 50%, the fixed-effect model was used. The publication bias assessed via visual inspection of the funnel plot suggested no significant risk of publication bias. The risk of bias in each study was evaluated according to the Cochrane instrument in both Asian population and Caucasian population [ Supplementary Figures S1 and S2 ].
Placebo effect in glycosylated hemoglobin between Asian and Caucasian population in antidiabetic treatment
In SU treatment group, the use of placebo led to a nonsignificant HbA1c change from baseline (MD, 0.187%; 95% CI, −0.144-0.518%; P = 0.269) in Caucasian population. There was no study in Asian population. In MET treatment group, the placebo effect led to a nonsignificant HbA1c change of 0.127% (95% CI, −0.360-0.613%; P = 0.610) in Caucasian population and also a nonsignificant HbA1c change of 0.140% (95% CI, −1.330-1.611%; P = 0.852) in Asian population. In AGI treatment group, the placebo effect resulted in an HbA1c change of 0.014% without significance (95% CI, −0.275-0.304%; P = 0.923) in Caucasians and resulted in a nonsignificant HbA1c change of −0.070% (95% CI, −0.562-0.421%; P = 0.779) in Asians. In TZD treatment group, the placebo effect led to a nonsignificant HbA1c change of 0.130% (95% CI, −0.174-0.433%; P = 0.402) in Caucasians as well as a nonsignificant HbA1c change of −0.036% (95% CI, −0.962-0.890%; P = 0.939) in Asians. In DPP-4i treatment group, the placebo effect led to a significant decrease in HbA1c (MD, −0.193%; 95% CI, −0.311-−0.075%; P = 0.001) in Caucasian population and also a significant reduction of HbA1c (MD, −0.162%; 95% CI, −0.289-−0.035%; P = 0.012) in Asian population. In SGLT2i treatment group, the placebo effect resulted in a significant decrease in HbA1c (MD, −0.230%; 95% CI, −0.340-−0.121%; P < 0.001) in Caucasians while it resulted in a nonsignificant HbA1c change of − 0.047% (95% CI, −0.543-0.449%; P = 0.853) in Asian population. In GLP-1RA treatment group, the placebo effect led to an HbA1c change of −0.172% (95% CI, −0.383-0.038%; P = 0.109) without significance in Caucasians and also a nonsignificant HbA1c change of −0.214% (95% CI, −0.448-0.021%; P = 0.074) in Asians [ Table 2 ]. Comparisons of the placebo effect in HbA1c changes relative to baseline indicated that no significant difference was found between Asian and Caucasian population in MET, AGI, TZD, DPP-4i, SGLT-2i, and GLP-1RA treatment. Since no studies of Asian population in SU treatment, it was concerned lack of evidence for comparing the Asian and Caucasian population in this category [ Table 2 and Supplementary Figures S3-S15].
Placebo effect in body weight between Asian and Caucasian population in antidiabetic treatment
In SU treatment group, the placebo effect resulted in a significant weight decrease (MD, −0.833 kg; 95% CI, −1.423-−0.243 kg; P = 0.006) in Caucasian population. No data were found with placebo effect in Asians. In MET treatment group, the placebo effect resulted in a nonsignificant weight change of −0.686 kg (95% CI, −2.823-1.451 kg; P = 0.529) in Caucasian population. No data were found with placebo effect in Asian population. In AGI treatment group, the placebo effect resulted in a nonsignificant weight change of −0.594 kg (95% CI, −1.607-0.420 kg; P = 0.251) in Caucasians and also a nonsignificant body weight change of 0.145 kg (95% CI, −1.543-1.834 kg; P = 0.866) in Asians. In TZD treatment group, the placebo effect led to a weight change of 0.018 kg without significance (95% CI, −0.945-0.982 kg; P = 0.970) † P value represented the significance of placebo effect on body weight changes from baseline in Caucasian population. in Caucasians and also a nonsignificant body weight change of −0.348 kg (95% CI, −1.494-0.797 kg; P = 0.551) in Asians. In DPP-4i treatment group, the placebo effect led to a weight change of −0.058 kg without significance (95% CI, −0.407-0.290 kg; P = 0.743) in Caucasian population and a nonsignificant body weight change of −0.345 kg (95% CI, −0.854-0.164 kg; P = 0.184) in Asian population. In SGLT2i treatment group, the placebo treatment led to a weight change of −0.512 kg without significance (95% CI, −2.882-1.859 kg; P = 0.672) in Caucasians and also a nonsignificant body weight change of −0.399 kg (95% CI, −1.286-0.488 kg; P = 0.378) in Asian population. In GLP-1RA treatment group, weight change in placebo effect was −0.953 kg with significance (95% CI, −1.626-−0.280 kg; P = 0.006) in Caucasians, and in Asians, the placebo effect was associated with a significant body weight reduction (MD, −0.612 kg; 95% CI, −0.884-−0.339 kg; P < 0.001). Comparisons of the placebo effect in body weight changes from baseline indicated that no significant difference was found between Asian and Caucasian population in AGI, TZD, DPP-4i, SGLT-2i, and GLP-1RA treatment. Since no studies of Asian population in SU and MET treatment, it was concerned lack of evidence for comparing the Asian and Caucasian population in those treatments [ Table 3 and Supplementary Figures S16-S27 ].
Associated factors with placebo effect
Meta-regression analysis indicated that, in each antidiabetic treatment group, the HbA1c changes in placebo treatment were not associated with the baseline age, gender, BMI, baseline HbA1c, DM duration, or study duration, respectively. There was also no association between HbA1c change and weight change from baseline. Meta-regression analysis also suggested that the weight change was not associated with the baseline age, gender, baseline BMI, duration of diabetes, study duration, baseline HbA1c, and the HbA1c changes from baseline in each antidiabetic treatment [Supplementary Table S3] .
dIscussIon
With the aim of comparisons between Asian and Caucasian population of the placebo effect, this meta-analysis indicated that the overall difference of the placebo effect in HbA1c changes from baseline was not significant, and the difference of the placebo effect in body weight changes from baseline between the two populations was neither significant in the seven kinds of antidiabetic treatments in T2DM. However, it is clear that there was a reduction of HbA1c and body weight due to placebo in each population. These data were based on a large dataset of placebo treatment including 63 studies in Asians and 262 studies in Caucasians. Moreover, placebo effect on HbA1c change or body weight change was not associated with baseline age, gender, BMI, baseline HbA1c, duration of diabetes, and study duration both in Asians and Caucasians.
The term "'placebo effect" was first introduced by Graves in 1920. [23] A placebo treatment may be administered through ingestion, injection, inhalation, insertion into a body cavity, or topical application. Placebo effect in T2DM might be associated with the optimal dietary treatment as well as physical activity and exercise for the glucose control and body weight control, besides medication therapy. Some evidence indicated that the dietary treatment for the glucose control might reduce HbA1c by 0.12~0.5% and also associated with weight change by −0.84~1.39 kg. [24] [25] [26] Physical activity and exercise were also suggested to improve the glucose control in people with T2DM with an average decrease in HbA1c by 0.4~0.6%. [3] [4] [5] All the above may contribute to the placebo effect on glucose control and body weight control. In this meta-analysis, we summarized the exact placebo effect in Caucasian population as well as in Asian population with different treatments for T2DM.
So far, mechanisms that underlie placebo effect are still not clearly understood. As Shapiro et al. indicated, [6] the reasons might fall within one of the three general categories. First, patient variables might be associated with placebo effect, including the attitude toward the physician, the treatment, and the illness, as well as including the levels of anxiety and expectation. However, in this meta-analysis, we could not collect these data from published trials to make further comparisons. Second, the physician variables may be another factor, including the doctor's credibility, enthusiasm, authority, empathy, and sympathy, which was also lack of evidence in this study. Third, there might be associated with situational variables, including the location and form of treatment. However, in this study, we compared placebo effect in glucose control and body weight change between Caucasian and Asian population in all the seven kinds of antidiabetic treatments but found no significant difference. Other possible reasons for placebo effect, as indicated by Gowdey [2] in his review of placebo pharmacology, the influence of expectations might play a role, which could not be confirmed in our study because of no evidence. Besides medication therapy, mechanisms for placebo effect in T2DM might be associated with the optimal dietary approach as well as physical activity to control hyperglycemia in T2DM.
[2] Several reviews and meta-analyses [3, 4, 24] indicated that diet and exercise could produce significant improvements in glucose control in people with T2DM. The difference of diet approach between Asian and Caucasian population was reported as the different composition of diet; however, with the rapid development of Asian, the western diet became more and more popular in Asian countries and the difference became smaller and smaller. The difference of physical activity between the two ethnicities was seldom reported and studied; therefore, all the above possible causes or mechanisms that might be associated with the placebo effect in T2DM treatments may not be significantly different between Caucasian and Asian population.
In a recently reported review, Kaptchuk and Miller [7] suggested that the therapeutic benefits associated with placebo effects did not alter the pathophysiology of diseases beyond their symptomatic manifestations. The observation from our mate-analysis supported the above conclusion. Ulteriorly, we proposed that the placebo effect in HbA1c changes and body weight changes of anti-diabetes treatment were comparable between Caucasians and Asians although there were evidence indicating that the pathophysiology of insulin secretion and insulin resistance was not the same between the two ethnicities. [9, 14] What's more, meta-regression analysis from our study also indicated that the placebo effect on HbA1c changes as well as on weight changes from baseline was not associated with baseline factors although the baseline BMI levels were significantly lower in Asians than that in Caucasians.
Certainly, as a meta-analysis, our meta-analysis has some limitations that we will better list here. First, the inclusion criteria and the baseline characteristics such as age, BMI, and duration of diabetes were different across studies, which caused a high level of heterogeneity. However, with the aim of comparisons between Asian and Caucasian population of the placebo effect, we used the random-effect model for analysis when the level of heterogeneity was high and also performed sensitivity analysis. We had also made meta-regression analysis to find if the baseline characteristics were the associated factors. Second, the data on placebo effects on glucose control or body weight control in each trial were used as the parameters in this meta-analysis, but not the pooled, patient-level data, which should be more useful to make a conclusion. However, these data are seldom available because most trials are sponsored by the industry. Therefore, we used the parameters in each trial as surrogates. Third, since no studies of Asian population in SU and MET treatments when we made comparisons of the placebo effect on HbA1c and body weight changes from baseline, it is concerned lack of evidence for comparing the Asian and Caucasian patients in those categories. Moreover, publication bias may also have effects on the results of placebo effects in this meta-analysis; however, a funnel plot assessment was carried out to minimize the risk of publication bias.
In a word, our results from this meta-analysis should be interpreted cautiously. The overall difference of the placebo effect on HbA1c changes as well as on body weight changes was not significant between Asian and Caucasian T2DM patients, but it is clear that there was a reduction of HbA1c and body weight due to placebo in each population. The placebo effect was not associated with baseline age, gender, baseline BMI, baseline HbA1c, duration of diabetes, or study duration.
Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest. 
Supplementary
